All Photos(1)

Key Documents

COO/COA

View All Documentation

E-067

Ethosuximide solution

Name: Ethosuximide solution
Brand: CERILLIAN

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant^®

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₇H₁₁NO₂

CAS Number:

77-67-8

Molecular Weight:

141.17

EC Number:

200-659-6

UNSPSC Code:

41116107

This product is discontinued. Contact Technical Servicefor assistance.

grade

certified reference material

feature

Snap-N-Spike^®/Snap-N-Shoot^®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant^®

concentration

1.0 mg/mL in methanol

format

single component solution

storage temp.

−20°C

SMILES string

CCC1(C)CC(=O)NC1=O

InChI

1S/C7H11NO2/c1-3-7(2)4-5(9)8-6(7)10/h3-4H2,1-2H3,(H,8,9,10)

InChI key

HAPOVYFOVVWLRS-UHFFFAOYSA-N

Gene Information

human ... CACNA1G(8913) , CACNA1H(8912) , CACNA1I(8911)

General description

Ethosuximide is an anticonvulsant specifically used to treat absence seizures. This Snap-N-Spike^® Reference Solution is suitable for LC/MS or GC/MS applications in clinical toxicology, forensic analysis, urine drug testing, or pharmaceutical research.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany

Snap-N-Shoot is a registered trademark of Cerilliant Corporation

Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

related product

Product No.

Description

Pricing

Signal Word

Danger

Hazard Statements

H225,H301 + H311 + H331,H370

Precautionary Statements

P210 - P280 - P301 + P310 + P330 - P302 + P352 + P312 - P304 + P340 + P311

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Target Organs

Eyes

Storage Class Code

3 - Flammable liquids

WGK

WGK 1

Flash Point(F)

49.5 °F - closed cup

Flash Point(C)

9.7 °C - closed cup

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

EU REACH Annex XVII (Restriction List)

CAS No.

67-56-1

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Effects of early long-term treatment with antiepileptic drugs on development of seizures and depressive-like behavior in a rat genetic absence epilepsy model.

Emilio Russo et al.

Epilepsia, 52(7), 1341-1350 (2011-06-04)

Depression is most commonly associated with epilepsy. Recent reports have suggested a putative relationship between seizure development and onset of depressive behavior, whereas others proposed that two clinical entities might represent different neuropathologic aspects of the same neurologic disorder. The

Non-convulsive status epilepticus of frontal origin in mucopolysaccharidosis type II successfully treated with ethosuximide.

Paolo Bonanni et al.

Developmental medicine and child neurology, 54(10), 961-964 (2012-03-15)

At 7 years of age, a female with mucopolysaccharidosis type II (MPS II) showed a sudden deterioration in neurological function, a sleep disorder, and progressive behavioural impairment. Electroencephalography was performed 1 year and 8 months after the onset of the

Ethosuximide and phenobarbital promote wound healing via enhancing collagenization.

Dema M Ajwee et al.

Chemical biology & drug design, 79(1), 137-142 (2011-02-22)

The fact that ethosuximide (ETO), phenobarbital (PHO), and barbituric acid (BARB) share structural and pharmacophoric homologies with phenytoin and allantoin, both known to have significant wound-healing properties, prompted us to evaluate them as wound-healing agents. Accordingly, ETO-, PHO-, and BARB-containing

Ethosuximide reduces epileptogenesis and behavioral comorbidity in the GAERS model of genetic generalized epilepsy.

Gabi Dezsi et al.

Epilepsia, 54(4), 635-643 (2013-03-08)

Ethosuximide (ESX) is a drug of choice for the symptomatic treatment of absence seizures. Chronic treatment with ESX has been reported to have disease-modifying antiepileptogenic activity in the WAG/Rij rat model of genetic generalized epilepsy (GGE) with absence seizures. Here

Does antiepileptogenesis affect sleep in genetic epileptic rats?

Gilles van Luijtelaar et al.

International journal of psychophysiology : official journal of the International Organization of Psychophysiology, 85(1), 49-54 (2011-09-29)

Recently it was established that early long lasting treatment with the anti-absence drug ethosuximide (ETX) delays the occurrence of absences and reduces depressive-like symptoms in a genetic model for absence epilepsy, rats of the WAG/Rij strain. Here it is investigated

View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service